吉西他滨联合卡培他滨治疗蒽环类耐药性晚期乳腺癌的临床效果和安全性分析

Abstract
Figure/Table
References (16)
Related Citation (15)

Download: PDF (0 KB) HTML (40 KB)
Export: BibTeX | EndNote (RIS)

Abstract ObjectiveTo explore the clinical efficacy and safety of Gemcitabine combining with Capecitabine in the treatment of advanced breast cancer with Anthracycline resistance.MethodsFrom June 2013 to November 2015,79 patients definitely diagnosed as advanced breast cancer with Anthracycline-resistant in our hospital were enrolled in the study and randomly assigned to control group (n=39)and observation group (n=40).In the control group,patientswere treated with Docetaxel and Capecitabine,while in the observation group,Gemcitabine combined with Capecitabine was used.After 2 cycles of treatment,the difference of clinical curative effect,the digestive tract discomfort inⅢandⅣdegrees and the occurrence of side effects such as bonemarrow suppression were compared between the two groups.ResultsThe total remission rate in the observation group was 47.50%,was higher than that in the control group (25.64%), the difference was statistically significant(P<0.05);the clinical total benefit rate in the control group was 76.92%,while the observation group was 80.00%,had no statistically significant difference between two groups(P>0.05);the incidence of digestive tract discomfort in degreeⅢ andⅣ and myelosuppression in the observation group was 17.50%and 22.50%,was lower than those of the control group (38.46%,43.59%),and the overall incidence of the digestive tract discomfort in degreeⅢandⅣand myelosuppression between the two groups had statistically significant difference (P< 0.05).ConclusionCombination of Gemcitabine and Capecitabine in the treatment of advanced breast cancer with Anthracycline-resistanthas a great effect,with few adverse reactions,it isworthy of promotion.

Key words： Gemcitabine Capecitabine Drug resistance Advanced breast cancer Curative effect Safety

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	GUOQing-sen

Cite this article:

GUOQing-sen. Analysis of the clinical efficacy and safety of Gem citabine combined with Capecitabine in the treatment of advanced breast cancer with Anthracycline resistance[J]. 中国当代医药, 2016, 23(33): 94-97.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2016/V23/I33/94

[1]	蔡力力，杨波，卢学春，等.免疫功能检测对评估细胞因子诱导的自体杀伤细胞治疗老年血液肿瘤疗效的研究[J].中国实验血液学杂志，2015，18（5）：1250-1255.
[2]	刘大海，卢振铎.新辅助化疗方案治疗局部晚期乳腺癌60例的疗效分析[J].中国新药杂志，2013，21（9）：1007-1009.
[3]	金从国，王熙才，伍治平，等.癌症患者外周血T细胞亚群水平及临床意义[J].肿瘤研究与临床，2013，15（1）：33-34.
[4]	孙燕，石远凯.临床肿瘤内科手册[M].5版.北京：人民卫生出版社，2007：476-491.
[5]	吴梅红，王雅杰.吉西他滨联合卡培他滨治疗蒽环类和紫杉类药物耐药晚期乳腺癌的临床观察[J].中华临床医师杂志（电子版），2011，5（2）：130-132.
[6]	Garacia E，Picaa F，Sinibaldi-Vallebona P，et al.Thymosin α1 in combination with cytokines and chemotherapy for the treatment of cancer[J].Int Immunopharmacol，2013，3：1145-1150.
[7]	李伟，王冰涛，尚宏清.保乳手术与改良根治术治疗早期乳腺癌的临床疗效比较[J].局解手术学杂志，2014，23（1）：79-81.
[8]	张保宁，张斌，唐中华，等.中国乳腺癌手术治疗10年的发展与变迁[J].中华肿瘤杂志，2013，8（34）：582-587．
[9]	肖华伍，欧阳取长.含卡培他滨方案治疗复发转移性乳腺癌的临床观察[J].中国肿瘤临床与康复，2013，19（3）：221-223.
[10]	王峥，康华峰，王西京，等.吉西他滨联合卡培他滨治疗蒽环类和紫杉类耐药的转移性乳腺癌[J].现代肿瘤医学，2014，22（10）：2031-2033.
[11]	Rha SY，Moon YH，Jeung HC，et al.Gemcitabinemonotherapyassalvage chemotherapy in heavily pretreatedmetastatic breast cancer[J].BreastCancer Res Treat，2015，90（3）：215．
[12]	叶金辉，蔡悦成，王向明，等.吉西他滨联合卡培他滨治疗耐药转移性乳腺癌的临床观察[J].实用癌症杂志，2013，27（5）：489．
[13]	赵颖，傅强，谢敬东.吉西他滨联合卡培他滨治疗耐药转移性乳腺癌68例临床研究[J].中国当代医药，2013，19 （7）：35-36.
[14]	刘桂兰，冯艳红，侯慧科，等.吉西他滨联合卡培他滨治疗蒽环类耐药的转移性乳腺癌的临床疗效和安全性分析[J].肿瘤药学，2013，3（5）：357-360.
[15]	狄晓鸿，吕瑞.TP化疗方案联合参芪扶正注射液治疗晚期卵巢癌的临床观察[J].西部中医药，2015，28（8）：1-2.
[16]	高琴，张丹丹，白帆，等.紫杉醇联合铂类方案治疗中晚期宫颈癌患者的临床疗效及对血清CYFRA21-1、SCCAg的影响[J].疑难病杂志，2015，14（1）：53-56.